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S U M M A R Y
Objectives: To clarify the incidence and prognosis of early-onset (EOD) and late-onset (LOD) GBS disease
in Japan. To evaluate the inﬂuence of national guidelines issued in 2008 on the epidemiology of GBS
disease.
Methods: Retrospective nationwide questionnaire surveillance on culture-conﬁrmed GBS infections
between 2004 and 2010.
Results: Eighty-eight EOD and 162 LOD cases were reported from 152 participating hospitals. The case
fatality of EOD was 13.6% and of LOD was 8.0%. Premature birth <37 weeks (p < 0.001) and low birth
weight <2500 g (p < 0.001) were signiﬁcantly associated with EOD mortality. A high rate of neurological
sequelae was noted in meningitis in EOD (8/24) and LOD (29/85) cases. Based on a live-birth number of
438 359 and inborn case numbers of 36 EOD and 42 LOD, the incidence of EOD and LOD were estimated
to be 0.08 (95% conﬁdence interval (CI) 0.06–0.11)/1000 and 0.10 (95% CI 0.07–0.12)/1000 live-births,
respectively. Before (2004–2008) and after (2009–2010) the issue of guidelines, the mortality of EOD
(from 14.8% to 11.8%) and LOD (from 9.8% to 2.5%) improved, but the incidence was unchanged.
Conclusions: The incidence of EOD and LOD is apparently low in Japan, but the mortality and morbidity
rates remain substantial. The issue of national guidelines did not affect the incidence.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Group B Streptococcus (GBS, Streptococcus agalactiae) is a
leading cause of invasive infections such as sepsis and meningitis
in infants aged younger than 3 months. The infections are classiﬁed
as early-onset disease (EOD) at age 0–6 days, and as late-onset
disease (LOD) at age 7–89 days. Guidelines from the Centers for
Disease Control and Prevention (CDC) for the prevention of EOD
were issued in the USA in 1996, and updated in 2002 and 2010.1–3
Implementation in the USA and other high-income countries has
led to a signiﬁcant decline in the incidence of EOD, but has had no
effect on the incidence of LOD.4–6
In Japan, national guidelines to prevent vertical GBS transmis-
sion were issued in 2008 and revised in 2011.7 The Japanese
revised guidelines recommend cultures from the vagina, perine-
um, and rectum in all pregnant women at 33–37 weeks of
gestation. The use of intrapartum antimicrobial prophylaxis (IAP)
is indicated for (1) women whose previous infant had GBS disease,
(2) women with a positive GBS culture, except those undergoing an* Corresponding author. Tel.: +81 78 997 2200; fax: +81 78 993 3728.
E-mail address: kskmatsu@s4.dion.ne.jp (K. Matsubara).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.11.027elective cesarean section, and (3) women with an unknown GBS
status at delivery irrespective of gestational week; however, these
Japanese guidelines are not based on the epidemiology of neonatal
GBS infections in Japan, but rather on that of the USA.
A recent systematic review indicated that the global burden of
GBS disease is still high in both EOD and LOD, with substantial
mortality and morbidity.4,5 The review also showed considerable
geographic differences in the incidence and prognosis;4,5 however
limited data on neonatal GBS infections are available for Asian
countries,4,8,9 and most have been derived from a single-center
study.8 In Japan, the ﬁrst to fourth nationwide surveillances were
conducted between 1983 and 2003; however, these reports had
several problems when compared with data from other coun-
tries.6,8–14 First, they analyzed patients without discriminating
culture-conﬁrmed cases from probable cases not proven by
culture. Second, they were not written in English, although some
parts of the ﬁrst three studies were later published in English.15
Third, in Japan, 48–49% of newborns are born in private clinics
without pediatricians and/or neonatologists,16 and newborns with
EOD occurring under these circumstances must be transferred.
Thus, the birth place is a worthwhile subject, but the prognosis
with regard to the different birth places has not been addressed.
Finally, the incidence of EOD and LOD has not been assessed.ses. Published by Elsevier Ltd. All rights reserved.
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EOD and LOD between 2004 and 2010. Our aim was to answer the
aforementioned unresolved concerns and to evaluate if the
national guidelines have inﬂuenced the clinical presentation and
incidence of neonatal GBS disease.
2. Methods
2.1. Study setting and design
A retrospective questionnaire surveillance was conducted from
January 1, 2004 to December 31, 2010. We mailed structured
survey forms to 498 hospitals where education programs
authorized by the Ministry of Health, Labor and Welfare have
been adopted for postgraduate clinical training. Information was
obtained based on the discharge register of each hospital. The
study was approved by the Ethics Committee of Sanno Hospital,
Tokyo; informed consent was not required.
2.2. Data collection and case deﬁnition
Data collection included (1) number of deliveries and live-
births, (2) number of maternal transfers and neonatal transfers, (3)
implementation (or not) of GBS prevention practices from either
the CDC or Japanese guidelines, and the time if implemented, (4)
infantile and maternal demographic features, (5) initial symptoms,
diagnosis, and bacteria isolation site of EOD and LOD cases, (6) case
fatality and neurological sequelae that were determined at
hospital discharge by chart review, and (7) culture screening for
mothers whose babies had EOD and LOD. Four obstetric risk factors
were also documented: preterm birth, premature rupture of
membranes for >18 h, intrapartum fever (>38 8C), and previous
sibling with GBS disease.
Preterm birth was deﬁned as <37 weeks of gestation; the
number of days of gestation was not collected. We deﬁned
invasive GBS disease as laboratory isolation of S. agalactiae from a
normally sterile site (blood, cerebrospinal ﬂuid (CSF), or joint
aspirate) with any clinical signs. Pneumonia is a respiratory
distress syndrome with a radiological appearance of streaky
opacity or conﬂuent lobar opaciﬁcation that commonly requires
mechanical ventilation in addition to a positive blood culture
result.
2.3. Microbiology
GBS serotyping was determined using a commercially available
kit (Denka Seiken, Tokyo).
2.4. Estimation of the incidence of EOD and LOD
To estimate the institution-based incidence, we ﬁrst counted
the number of EOD and LOD infants who were born from mothers
obstetrically managed throughout pregnancy at the relevant
hospital (inborn cases). We excluded from the calculation those
GBS cases whose mothers were transferred from another hospital
within approximately 2 weeks before delivery (maternal transfer
cases) and GBS cases that were born outside and transferred after
the onset of the disease (outborn cases). Second, we collected the
number of live-births at each hospital, excluding delivery after
maternal transfer. The incidence was calculated for inborn cases
only.
2.5. Impact of national guidelines
To determine the effect of the Japanese national guidelines
issued in June 2008, we divided the study period into two periods,before (2004–2008, ﬁrst period) and after (2009–2010, second
period) the guidelines.
2.6. Statistics
Differences between categorical variables were assessed using
the Chi-square test, with Yates’ correlation when appropriate. For
the assessment of differences between nominal variables, the
Student’s t-test or the Mann–Whitney U-test was used. p-Values of
<0.05 were considered signiﬁcant. SSPS for Windows (version
19.0, SPSS Inc., Chicago, IL) was used to perform the statistical
analysis.
3. Results
One hundred ﬁfty-two hospitals participated in this study (see
Appendix). Of these, 14 hospitals managed only outborn infants
because of the absence of an obstetric department. Of the
remaining 138 hospitals, 62 had neonatal intensive care units
and 76 were regional centers.
3.1. Study populations and demographic features
During the 7-year study period, 88 EOD and 162 LOD cases were
reported. Baseline data are shown in Table 1. Maternal age of EOD
infants (31.0  5.0 years) was signiﬁcantly older than that of LOD
infants (29.4  4.5 years) (p < 0.001). All values other than maternal
age in Table 1 did not differ signiﬁcantly between EOD and LOD
infants. The age distribution at diagnosis and gestational age at birth
are shown in Figure 1. The median age of LOD infants was 28.5 days
(range 7–88 days), and 80 of 88 EOD cases were diagnosed at 0–2
days. Preterm births included 25.0% EOD and 28.4% LOD infants.
3.2. Serotype distribution
Among 64 isolates serotyped, the distribution was Ia (n = 7), Ib
(n = 1), III (n = 8), V (n = 1), VI (n = 1), and VIII (n = 1) in EOD, and Ia
(n = 13), Ib (n = 6), III (n = 24), IV (n = 1), and V (n = 1) in LOD.
3.3. Characteristics of infants with group B streptococcal disease
The initial symptoms, diagnosis, GBS isolation site, and
outcome are shown in Table 2. The presentation of shock was
highly associated with a fatal outcome (5/9 in EOD and 2/4 in LOD).
The most common diagnosis in EOD was sepsis, followed by
meningitis and pneumonia. Among LOD cases, meningitis and
sepsis were common, followed by arthritis (three cases involved
hip joints and one case involved the knee joint) and cellulitis (three
involved inguinal regions, one the buttock region, and one involved
the cervical region).
The case fatality of EOD was 13.6%, which was much higher than
that of LOD (8.0%), however the difference did not reach
signiﬁcance (Table 2). When the study period was divided into
the two periods mentioned above, mortality declined from 14.8%
(8/54) in the ﬁrst period to 11.8% (4/34) in the second period
among EOD, and from 9.8% (11/112) to 2.5% (2/50) among LOD.
Case fatality in total was signiﬁcantly higher in infants born
prematurely: 21.3% (10/47) at 33 weeks of gestation, 15.0% (3/20)
at 34–36 weeks of gestation, and 4.9% (9/183) at 37 weeks of
gestation (Chi-square for trend p < 0.001). This signiﬁcance was
observed in EOD cases (40.9% (9/22) in preterm vs. 4.5% (3/66) in
term babies; p < 0.001; odds ratio 14.3, 95% conﬁdence interval
(CI) 3.5–61.2), while not in LOD cases (8.7% (4/46) in preterm vs.
7.8% (9/116) in term babies). Similarly, case fatality was
signiﬁcantly associated with birth weight in infants with EOD
(37.5% (9/24) <2500 g vs. 4.7% (3/64) 2500 g, p < 0.001; odds
Table 1
Baseline characteristics of infants with early-onset and late-onset group B streptococcal disease
Early-onset disease (EOD), n = 88 Late-onset disease (LOD), n = 162
Male:female 50:38 89:73
Birth weight (g), for 88 EOD, 160 LOD
Median/range 3020/556–4340 2849/435–3804
Low birth weight (<2500 g) 21 (23.9%) 50 (30.9%)
Very low birth weight (1000–1499 g) 5 12
Extremely low birth weight (<1000 g) 8 11
Gestational age (weeks)
Median/range 39/22–42 38/22–42
Preterm births (<37 weeks) 22 (25.0%) 46 (28.4%)
Early preterm births (22–33 weeks) 18 29
Late preterm births (34–36 weeks) 4 17
Twins 3 9
Maternal agea (years), for 82 EOD, 115 LOD
Mean  SD 31.1  5.0 29.4  4.5
Median/range 32/22–42 30/19–39
<20 years 0 1
Cesarean sections, for 88 EOD, 151 LOD 18 (20.5%) 51 (33.8%)
Mothers with 1 risk factors 30 (34.1%) 48 (29.6%)
Prematurity 21 48
Intrapartum fever 10 1
Premature rupture of membranes 5 1
Previous sibling with GBS disease 0 0
Birth place
Hospital without maternal transfer (inborn cases) 36 42
Hospital within 2 weeks after maternal transfer (maternal transfer cases) 7 15
Hospital or clinic other than managed center (outborn cases) 44 105
Home 1 0
SD, standard deviation.
a p < 0.001 (EOD vs. LOD).
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<2500 g vs. 6.2% (7/113) 2500 g). Mortality in EOD did not differ
among birth places: 13.9% (5/36) in inborn cases, 28.6% (2/7) in
maternal transfer cases, and 11.1% (5/45) in outborn cases.
As for morbidity, EOD and LOD cases had sequelae in 13.6% and
21.0%, respectively (Table 2). The morbidity rate was not different
between preterm and term neonates. A high rate of neurological
sequelae was noted in meningitis in EOD (33.3%, 8/24) and LOD
(34.1%, 29/85; p < 0.001 vs. non-meningitis LOD (6.6%, 5/76))
cases. Speech or mental delay (n = 23), epilepsy (n = 13), cerebral
palsy (n = 9), brain atrophy (n = 7), hydrocephalus (n = 4), visual
impairment (n = 3), and deafness (n = 2) were documented.
Cellulitis and arthritis had an excellent prognosis without any
fatality or complications.
Of 88 EOD, 51 (58.0%) mothers underwent culture screening
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Figure 1. Age distribution at disease onset and gestational age at birth.unknown. Nine of 25 mothers whose culture time was known were
screened before 33 weeks of gestation, i.e., in an inappropriate
period according to the Japanese guidelines. The majority (28/51)
of mothers were screened GBS-negative and 23 were positive;
however, culture results did not affect the mortality or morbidity
of the 51 EOD infants whose mothers underwent culture screening.
3.4. Implementation of prophylaxis guideline
The time when prophylaxis guidelines were introduced differed
among the hospitals. Figure 2 shows the cumulative change in the
introduction in 138 hospitals that had a department of obstetrics.
The rate was 42.0% (58/138) at the start of the study in January
2004, and rapidly increased in 2008, when the national guidelines
were issued. At the end of the study, more than 90% (125/138) of
the hospitals had adopted the guidelines. Among 36 inborn EOD
cases, 27 were born at institutions after guideline introduction, and
nine were born before their introduction; however, the mortality
of the 36 inborn cases did not differ between individuals born at
hospitals before (11%, 1/9) or after (11%, 3/27) the adoption of a
preventive strategy.
3.5. Incidence of EOD and LOD
Finally, we attempted to assess the incidence of EOD and LOD.
The total number of live-births as deﬁned above was 438 359 in the
138 hospitals between 2004 and 2010. The EOD and LOD inborn
cases numbered 36 and 42, respectively. Thus, the estimated
incidence of EOD and LOD were 0.08 (95% CI 0.06–0.11)/1000 live-
births and 0.10 (95% CI 0.07–0.12)/1000 live-births, respectively.
No signiﬁcant differences were observed in the EOD and LOD
incidence between the ﬁrst period (0.08 (95% CI 0.05–0.10)/1000
live-births, 23/305 210, and 0.10 (95% CI 0.06–0.13)/1000 live-
births, 29/305 210) and the second period (0.10 (95% CI 0.07–0.12)/
1000 live-births, 13/133 329, and 0.10 (95% CI 0.07–0.12)/1000
live-births, 13/133 329), respectively.
Table 2
Characteristics of infants with group B streptococcal disease
Early-onset disease (EOD), n = 88 Late-onset disease (LOD), n = 162
Initial symptomsa
Fever 31 (35.2%) 106 (65.4%)
Respiratory (apnea, grunting, respiratory distress, and/or retraction) 57 (64.8%) 51 (31.5%)
Central nervous system (convulsions and/or altered consciousness) 18 (20.5%) 18 (11.1%)
Vomiting 3 (3.4%) 9 (5.6%)
Shock 9 (10.2%) 4 (2.5%)
Diagnosis
Sepsis 55 (62.5%) 65 (40.1%)
Meningitisb 24 (27.3%) 85 (52.5%)
Pneumonia 9 (10.2%) 3 (1.9%)
Arthritis 0 4 (2.5%)
Cellulitis 0 5 (3.1%)
Bacterial isolation site
Blood alone 64 (72.7%) 73 (45.1%)
CSF + blood 19 (21.6%) 73 (45.1%)
CSF alone 5 (5.7%) 12 (7.4%)
Joint + blood 0 2 (1.2%)
Joint alone 0 2 (1.2%)
Outcome
Died 12 (13.6%) 13 (8.0%)
Survived with sequelae 12 (13.6%) 34 (21.0%)
CSF, cerebrospinal ﬂuid.
a Each infant had one or more symptoms.
b Cases with group B Streptococcus isolation from both blood and CSF are classiﬁed as meningitis.
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In this study, we detail the epidemiology of infantile invasive
GBS infections between 2004 and 2010 in Japan. This is of note
because data from Asian countries are sparse. One of the important
ﬁndings derived from this study are the remaining high mortality
and morbidity rates. The case fatality rates of 13.6% in EOD and
8.0% in LOD are comparable with recent global data showing the
mean rates in EOD and LOD to be 12.1% (95% CI 6.2–18.3) and 6.8%
(95% CI 4.3–9.4), respectively.4 However, our data are slightly
higher than those in the USA and high-income European
countries.4,6,10–14 When our study period is limited to 2009–
2010, fatality improved in EOD (11.8%) and LOD (2.5%).
We examined the association of several perinatal factors with
mortality. As in previous papers,10,14 prematurity and low birth
weight were signiﬁcantly linked to early-onset mortality. Further-
more, we hypothesized that transfer EOD cases would have a poor
prognosis, since there is evidence of an association between the
duration of transport and increased mortality. A cohort study of
4966 transferred neonates in Osaka, Japan, showed that those
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Figure 2. Cumulative rate of adoption of preventive strategies in January each year
among 138 hospitals with a department of obstetrics.compared with those transported for between 30 and 59 min.17
However, our study did not show a signiﬁcant effect of different
birth place on the prognosis, suggesting that the perinatal transfer
network in Japan is functional.
Neurological sequelae were found in approximately a third of
infants with meningitis. This proportion is also comparable to that
of recently published studies, which have usually included
moderate to severe sequelae;18 however, the morbidity rate
may increase after long-term follow-up because cognitive
impairment and subtle neurodevelopmental and behavioral delay
may be identiﬁed later. In fact, neurological sequelae have been
shown to increase to as high as 44–50% of GBS meningitis at the age
of 5–6 years when mild disability is included in the analysis.19,20
Another important ﬁnding is an apparent low incidence of EOD
and LOD, which were stable from the ﬁrst to second study periods.
It is possible that GBS disease is underestimated since systematic
cultures are not performed, and there can be false-negative
cultures related to the very small volume of blood inoculated.
Alternatively, the low rates could be due to high levels of
transplacentally acquired protective antibodies in cord se-
rum.21,22 In addition, the low rates may reﬂect the prevalence
of less virulent strains. This and previous studies15,23,24 indicate
that serotypes VI and VIII predominate among pregnant women
carriers in Japan, while these strains are rarely isolated from EOD
neonates. Ethnic factors may also have a role in susceptibility to
GBS disease.
We should acknowledge the limitations in these estimates since
they were not population-based but institution-based in a
retrospective study. Neonatal GBS incidence based on capture–
recapture analysis has been reported in a nationwide fashion from
European countries.10–12 However, the function and location of the
hospitals participating in this study varied widely, and one or more
institutions were enrolled from 44 of 47 prefectures in Japan. We
therefore believe that there is minimal bias in enrollment.
Moreover, national statistics have indicated that the early neonatal
mortality rate due to perinatal infections was 2.3–2.7/100 000 live-
births in 2004–2010.16 Assuming that 40% of the fatal etiology is
attributable to GBS,25 0.9–1.1/100 000 live-births die as a result of
this pathogen. This ﬁgure is concordant with the EOD death rate of
1.1/100 000 live-births in our analysis. Thus, national statistics16
support the validity of our estimates.
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epidemiology of infantile GBS disease in Japan. Our results reveal a
very low incidence of EOD and LOD, but mortality and morbidity
rates remain substantial. There are signiﬁcant associations
between EOD case fatality and prematurity as well as low birth
weight, and between sequelae and the diagnosis of meningitis.
National guidelines have had no effect on the incidence of EOD but
have improved the prognosis. This study may serve as a baseline
for the development and implementation of further evidence-
based guidelines. We have planned a prospective, population-
based GBS case enrollment in Japan to more precisely determine
the epidemiology of GBS diseases.
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Appendix A
A.1. Participating hospitals, n = 152
Hokkaido Medical Center for Child Health and Rehabilitation,
Sapporo, Hokkaido; Sapporo Social Insurance General Hospital,
Sapporo, Hokkaido; Sapporo Tokushukai Hospital, Sapporo,
Hokkaido; Sapporo Hokuyu Hospital, Sapporo, Hokkaido; Nikko
Memorial Hospital, Muroran, Hokkaido; Hakodate Municipal
Hospital, Hakodate, Hokkaido; Asahikawa Medical University,
Asahikawa, Hokkaido; Kushiro Red Cross Hospital, Kushiro,
Hokkaido; Tomakomai City Hospital, Tomakomai, Hokkaido;
Engaru-Kosei General Hospital, Monbetsu, Hokkaido; Kuroishi
General Hospital, Kuroishi, Aomori; National Hirosaki Hospital,
Hirosaki, Aomori; Sendai City Hospital, Sendai, Miyagi; Saka
General Hospital, Shiogama, Miyagi; Yamagata City Hospital
Saiseikan, Yamagata; Iwate Medical University, Morioka, Iwate;
Odate Municipal General Hospital, Odate, Akita; Fukushima
Medical University, Fukushima; Gunma University Hospital,
Maebashi, Gunma; Gunma Children’s Medical Center, Shibukawa,
Gunma; Jichi Medical University, Shimono, Tochigi; Ibaraki Seinan
Medical Center Hospital, Sashima-gun, Ibaraki; Hitachi General
Hospital, Hitachi, Ibaraki; Saitama City Hospital, Saitama; Saitama
Medical Center, Kawagoe, Saitama; Koshigaya Municipal Hospital,
Koshigaya, Saitama; Kameda Medical Center, Kamogawa, Chiba;
Chiba Aoba Municipal Hospital, Chiba; Chiba Kaihin Municipal
Hospital, Chiba; Nippon Medical School, Chiba Hokusoh Hospital,
Inzai, Chiba; Sakura Hospital, Toho University Medical Center,
Sakura, Chiba; Teikyo University Chiba Medical Center, Ichihara,
Chiba; Matsudo City Hospital, Matsudo, Chiba; Tokyo Women’s
Medical Center, Yachiyo Medical Center, Yachiyo, Chiba; Asahi
General Hospital, Asahi, Chiba; Toranomon Hospital, Minato-ku,
Tokyo; Teikyo University School of Medicine, Itabashi-ku, Tokyo;
Showa University School of Medicine, Shinagawa-ku, Tokyo; Tokyo
Metropolitan Bokutoh Hospital, Sumida-ku, Tokyo; Tokyo
Women’s Medical University Medical Center East, Arakawa-ku,
Tokyo; Tokyo Teishin Hospital, Chiyoda-ku, Tokyo; Toho Universi-
ty Medical Center Omori Hospital, Ohta-ku, Tokyo; Juntendo
University School of Medicine, Bunkyo-ku, Tokyo; Tokyo Metro-
politan Children’s Medical Center, Fuchuu, Tokyo; Tokyo Nishi
Tokushukai Hospital, Showa, Tokyo; Nippon Medical School, Taga
Nagayama Hospital, Tama, Tokyo; Tama-Hokubu Medical Center,
Higashimurayama, Tokyo; Saiseikai Yokohamashi Nanbu Hospital,
Yokohama, Kanagawa; Yokohama City University Medical Center,Yokohama, Kanagawa; St. Marianna University, School of Medi-
cine, Yokohama-City Seibu Hospital, Yokohama, Kanagawa; Showa
University Fujigaoka Hospital, Yokohama, Kanagawa; Odawara
Municipal Hospital, Odawara, Kanagawa; National Hospital
Organization Kanagawa Hospital, Hadano, Kanagawa; Nippon
Medical School Musashi Kosugi Hospital, Kawasaki, Kanagawa;
Teikyo University School of Medicine, Mizonokuchi Hospital,
Kawasaki, Kanagawa; Yokosuka City Hospital, Yokosuka, Kana-
gawa; National Hospital Organization Sagamihara National
Hospital, Sagamihara, Kanagawa; Kofu Kyoritsu Hospital, Kofu,
Yamanashi; Kashiwazaki General Hospital and Medical Center,
Kashiwazaki, Niigata; Nagano Red Cross Hospital, Nagano; Shinshu
University, School of Medicine, Matsumoto, Nagano; Nagano
Children’s Hospital, Azumino, Nagano; Saku Central Hospital,
Saku, Nagano; Iida Municipal Hospital, Iida, Nagano; Shizuoka Red
Cross Hospital, Shizuoka; Juntendo University Shizuoka Hospital,
Izunokuni, Shizuoka; Iwata City Hospital, Iwata, Shizuoka;
Shimada Municipal Hospital, Shimada, Shizuoka; Chuubu Rosai
Hospital, Nagoya, Aichi; Nagoya University Hospital, Nagoya,
Aichi; Meitetsu Hospital, Nagoya, Aichi; Nagoya City University
Hospital, Nagoya, Aichi; Nagoya Ekisaikai Hospital, Nagoya, Aichi;
Nagoya Daini Red Cross Hospital, Nagoya, Aichi; Aichi Prefectural
Colony Central Hospital, Kasugai, Aichi; Hekinan Municipal
Hospital, Hekinan, Aichi; Komaki City Hospital, Komaki, Aichi;
Aichi Children’s Health and Medical Center, Obu, Aichi; Toyota
Kosei Hospital, Toyota, Aichi; Toyota Memorial Hospital, Toyota,
Aichi; Okazaki City Hospital, Okazaki, Aichi; Gifu Prefectural
General Medical Center, Gifu; Tajimi Hospital, Tajimi, Gifu;
Takayama Red Cross Hospital, Takayama, Gifu; National Mie
Hospital, Tsu, Mie; Ishikawa Prefectural Central Hospital, Kana-
zawa, Ishikawa; National Hospital Organization Iou National
Hospital, Kanazawa, Ishikawa; Toyama Prefectural Central Hospi-
tal, Toyama; Faculty of Medical Science, University of Fukui,
Yoshida-gun, Fukui; Fukui Prefectural Hospital, Fukui; Fukui Red
Cross Hospital, Fukui; Saiseikai Shigaken Hospital, Ritto, Shiga;
Ohtsu Red Cross Hospital, Ohtsu, Shiga; Takashima Municipal
Hospital, Takashima, Shiga; Kyoto City Hospital, Kyoto; Kyoto
Katsura Hospital, Kyoto; Japan Baptist Hospital, Kyoto; Social
Insurance Kyoto Hospital, Kyoto; Kyoto University Hospital, Kyoto;
Japanese Red Cross Kyoto Daiichi Hospital, Kyoto; National
Hospital Organization Kyoto Medical Center, Kyoto; Osaka City
University Hospital, Osaka; Nakano Children’s Hospital, Osaka;
Nissei Hospital, Osaka; Chibune Hospital, Osaka; Osaka Red Cross
Hospital, Osaka; Yodogawa Christian Hospital, Osaka; Kitano
Hospital, Osaka; Matsushita Memorial Hospital, Moriguchi, Osaka;
Toyonaka Municipal Hospital, Toyonaka, Osaka; Hoshigaoka
Koseinenkin Hospital, Hirakata, Osaka; Minoh City Hospital,
Minoh, Osaka; Komatsu Hospital, Neyagawa, Osaka; Itami City
Hospital, Itami, Osaka; Japanese Red Cross Wakayama Medical
Center, Wakayama; Naga Hospital, Kinokawa, Wakayama; Yamato
Takada Municipal Hospital, Yamatotakada, Nara; Tenri Yorozu
Hospital, Tenri, Nara; Nishi-Kobe Medical Center, Kobe, Hyogo;
Kobe City Medical Center General Hospital, Kobe, Hyogo; Hyogo
Prefectural Tsukaguchi Hospital, Amagasaki, Hyogo; Himeji Red
Cross Hospital, Himeji, Hyogo; Ono Municipal Hospital, Ono,
Hyogo; Hyogo Prefectural Nishinomiya Hospital, Nishinomiya,
Hyogo; Kawasaki Medical School, Kurashiki, Okayama; Kurashiki
Medical Center, Kurashiki, Okayama; Kurashiki Central Hospital,
Kurashiki, Okayama; Tsuchiya General Hospital, Hiroshima;
Hiroshima City Funairi Hospital, Hiroshima; Onomichi General
Hospital, Onomichi, Hiroshima; Tottori Prefectural Central Hospi-
tal, Tottori; Shimane Prefectural Central Hospital, Izumo, Shimane;
Takamatsu Red Cross Hospital, Takamatsu, Kagawa; Kagawa
Prefectural Central Hospital, Takamatsu, Kagawa; Tokushima
Red Cross Hospital, Komatsujima, Tokushima; Kochi Health
Sciences Center, Kochi; Kyushu University Hospital, Fukuoka;
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